Home Apoptosis IAP antagonist AZD5582

research use only

AZD5582 IAP Antagonist

Cat.No.S7362

AZD5582, a novel small-molecule IAP inhibitor, binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP with IC50 values of 15, 21, and 15
AZD5582 IAP antagonist Chemical Structure

Chemical Structure

Molecular Weight: 1015.29

Jump to

Quality Control

Batch: Purity: 99.08%
99.08

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 Antiproliferative assay 48 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by Alamar Blue assay, GI50 = 0.00006 μM. 24320998
MDA-MB-231 Function assay 1 hr Binding affinity to cIAP1 in human MDA-MB-231 cells assessed as induction of protein degradation after 1 hr by ELISA, EC50 = 0.0001 μM. 24320998
MDA-MB-231 Apoptosis assay 0.5 to 1.5 nM 1 to 3 hrs Induction of apoptosis in human MDA-MB-231 cells assessed as caspase-3 cleavage at 0.5 to 1.5 nM preincubated for 1 to 3 hrs followed by compound-washout measured after 24 hrs by luciferase reporter gene assay 24320998
MDA-MB-231 Antitumor assay 0.1 to 3 mg/kg 2 weeks Antitumor activity against human MDA-MB-231 cells xenografted in CB17 SCID mouse assessed as tumor growth inhibition at 0.1 to 3 mg/kg, iv administered once a week for 2 weeks measured twice a week for 78 days 24320998
MDA-MB-231 Function assay 0.05 to 3 mg/kg 4 to 18 hrs Induction of caspase-3 cleavage in tumor of CB17 SCID mouse xenografted with human MDA-MB-231 cells at 0.05 to 3 mg/kg, iv after 4 to 18 hrs by ELISA 24320998
MDA-MB-231 Function assay 0.05 to 3 mg/kg up to 18 hrs Induction of cIAP1 degradation in tumor of CB17 SCID mouse xenografted with human MDA-MB-231 cells at 0.05 to 3 mg/kg, iv up to 18 hrs by ELISA 24320998
BT549 Growth inhibition assay Growth inhibition of human BT549 cells 24320998
MDA-MB-231 Apoptosis assay 0.5 to 1.5 nM 1 to 3 hrs Induction of apoptosis in human MDA-MB-231 cells assessed as cell death at 0.5 to 1.5 nM preincubated for 1 to 3 hrs followed by compound-washout measured after 72 hrs by MTS assay 24320998
MDA-MB-231 Function assay 1 uM 4 hrs Inhibition of XIAP-caspase-9 interaction in human MDA-MB-231 cells at 1 uM after 4 hrs by immunoprecipitation assay 24320998
MDA-MB-231 Function assay 0.03 to 1 nM 1 hr Binding affinity to cIAP2 in human MDA-MB-231 cells assessed as induction of protein degradation at 0.03 to 1 nM after 1 hr by Western blotting analysis 24320998
647V Growth inhibition assay Growth inhibition of human 647V cells 24320998
35612 Growth inhibition assay Growth inhibition of human 97-7 cells 24320998
MIAPaCa2 Growth inhibition assay Growth inhibition of human MIAPaCa2 cells 24320998
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

Water : 100 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 1015.29 Formula

C58H78N8O8

 Storage (From the date of receipt)
CAS No. 1258392-53-8 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles CC(C(=O)NC(C1CCCCC1)C(=O)N2CCCC2C(=O)NC3C(CC4=CC=CC=C34)OCC#CC#CCOC5CC6=CC=CC=C6C5NC(=O)C7CCCN7C(=O)C(C8CCCCC8)NC(=O)C(C)NC)NC

Mechanism of Action

Targets/IC50/Ki
cIAP1
(Cell-free assay)
15 nM
XIAP
(Cell-free assay)
15 nM
cIAP2
(Cell-free assay)
21 nM
In vitro
Human pancreatic cancer cells display different sensitivities to the synthetic IAP antagonist, AZD5582. Treating human pancreatic cancer cells with this compound differentially induces apoptosis, dependent on the expression of p-Akt and p-XIAP. It targets cIAP1 to induce TNF-α-induced apoptosis. This chemical induces a decrease of Mcl-1 protein, a member of the Bcl-2 family, but not that of Bcl-2 and Bcl-xL. HNSCC (head and neck squamous cell carcinoma) cell lines SCC25, Cal27, and FaDu show a dose-dependent cytotoxic effect after treatment with this antagonist.
In vivo
After AZD5582 treatment, tumor growth and weight decrease, whereas cleaved caspase 3 expression increases in Panc-1-derived xenograft model. When administered intravenously to MDA-MB-231 xenograft-bearing mice, this compound results in cIAP1 degradation and caspase-3 cleavage within tumor cells and causes substantial tumor regressions following two weekly doses of 3.0 mg/kg. Following a modest 0.5 mg/kg intravenous bolus dose of this compound in mice, unbound plasma levels remain above the concentrations at which apoptosis induction and cell death are observed in MDA-MB-231 cells over the course of several hours. Although cIAP1 degradation happens very quickly upon exposure to this compound in vivo, apoptosis induction (as measured by the amount of cleaved caspase-3) takes longer to reach a maximal effect. A single agent of this chemical does not exhibit broad-based cytotoxicity but instead should be employed in selected tumor settings expected to be sensitive to IAP inhibitors or in rational combinations with other targeted therapies. The dihydrochloride salt of this compound has sufficient aqueous solubility (>7 mg/mL at pH 4−6) to enable formulation for intravenous administration at the projected efficacious doses. With respect to chemical stability, this compound is found to be photostable and hydrolytically stable between pH 4−6, although some amide hydrolysis is observed under strongly acidic (pH < 1) and basic (pH > 8) conditions. In addition, the compound is stable in the plasma of multiple species, with no compound degradation observed after several hours under physiological conditions.
References

Applications

Methods Biomarkers Images PMID
Western blot XIAP
S7362-WB1
26314849

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map